Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
Updated: Oct 19, 2026
James Quigley's Stock Ratings
Goldman Sachs Analyst
James Quigley is an analyst at Goldman Sachs. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends.
Overall Average Return
-0.51%
Smart Score
Overall Average Return Percentile
35th
Number of Ratings
32
| Buy Now | Get Alert | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 03/02/2026 | NVO | Buy Now | Novo Nordisk | $38.42 | 6.72% | $63 → $41 | Downgrade | Buy → Neutral | Get Alert | |
| 12/09/2025 | KYMR | Buy Now | Kymera Therapeutics | $111.83 | 13.57% | $73 → $127 | Maintains | Overweight | Get Alert | |
| 11/28/2025 | NVO | Buy Now | Novo Nordisk | $38.42 | 40.55% | $60 → $54 | Maintains | Buy | Get Alert | |
| 09/12/2025 | NVS | Buy Now | Novartis | $150.20 | -21.44% | $119 → $118 | Downgrade | Neutral → Sell | Get Alert | |
| 06/03/2025 | KYMR | Buy Now | Kymera Therapeutics | $111.83 | -29.36% | $49 → $79 | Upgrade | Equal-Weight → Overweight | Get Alert | |
| 03/21/2025 | SNY | Buy Now | Sanofi | $39.64 | 63.97% | → $65 | Initiates | → Neutral | Get Alert | |
| 11/06/2024 | KYMR | Buy Now | Kymera Therapeutics | $111.83 | -56.18% | $45 → $49 | Maintains | Equal-Weight | Get Alert | |
| 09/05/2024 | NVS | Buy Now | Novartis | $150.20 | -19.44% | $119 → $121 | Downgrade | Buy → Neutral | Get Alert | |
| 08/14/2024 | KYMR | Buy Now | Kymera Therapeutics | $111.83 | -59.76% | $34 → $45 | Maintains | Equal-Weight | Get Alert | |
| 01/19/2024 | MOR | Buy Now | MorphoSys | — | — | — | Downgrade | Overweight → Equal-Weight | Get Alert | |
| 01/16/2024 | MOR | Buy Now | MorphoSys | — | — | — | Downgrade | Overweight → Equal-Weight | Get Alert | |
| 12/05/2023 | GRFS | Buy Now | Grifols | $7.64 | 37.43% | $10 → $10.5 | Maintains | Neutral | Get Alert | |
| 11/13/2023 | KYMR | Buy Now | Kymera Therapeutics | $111.83 | -78.54% | $37 → $24 | Maintains | Equal-Weight | Get Alert | |
| 10/13/2023 | MOR | Buy Now | MorphoSys | — | — | $3.7 → $9.2 | Upgrade | Underweight → Overweight | Get Alert | |
| 08/29/2023 | KYMR | Buy Now | Kymera Therapeutics | $111.83 | -66.91% | $39 → $37 | Maintains | Equal-Weight | Get Alert | |
| 08/07/2023 | GLPG | Buy Now | Galapagos | — | — | $42 → $40 | Maintains | Equal-Weight | Get Alert | |
| 08/01/2023 | GLPG | Buy Now | Galapagos | — | — | $42 → $42 | Reiterates | Equal-Weight → Equal-Weight | Get Alert | |
| 07/31/2023 | GLPG | Buy Now | Galapagos | — | — | $42 → $42 | Reiterates | Equal-Weight → Equal-Weight | Get Alert | |
| 07/24/2023 | GLPG | Buy Now | Galapagos | — | — | $42 → $42 | Reiterates | Equal-Weight → Equal-Weight | Get Alert | |
| 07/17/2023 | GLPG | Buy Now | Galapagos | — | — | $42 → $42 | Reiterates | Equal-Weight → Equal-Weight | Get Alert | |
| 06/26/2023 | GLPG | Buy Now | Galapagos | — | — | $42 → $42 | Reiterates | Equal-Weight → Equal-Weight | Get Alert | |
| 06/23/2023 | EVO | Buy Now | Evotec | $1.38 | 1059.42% | $12 → $16 | Upgrade | Equal-Weight → Overweight | Get Alert | |
| 06/20/2023 | GLPG | Buy Now | Galapagos | — | — | → $42 | Reiterates | → Equal-Weight | Get Alert | |
| 06/12/2023 | GLPG | Buy Now | Galapagos | — | — | → $42 | Reiterates | Equal-Weight → Equal-Weight | Get Alert | |
| 05/31/2023 | GLPG | Buy Now | Galapagos | — | — | $52 → $45 | Maintains | Neutral | Get Alert | |
| 05/09/2023 | KYMR | Buy Now | Kymera Therapeutics | $111.83 | -65.13% | $41 → $39 | Maintains | Equal-Weight | Get Alert | |
| 05/09/2023 | GLPG | Buy Now | Galapagos | — | — | $44 → $42 | Maintains | Equal-Weight | Get Alert | |
| 04/04/2023 | EVO | Buy Now | Evotec | $1.38 | — | — | Upgrade | Underweight → Equal-Weight | Get Alert | |
| 08/10/2022 | EVO | Buy Now | Evotec | $1.38 | 1059.42% | → $16 | Downgrade | Overweight → Underweight | Get Alert | |
| 01/14/2022 | MOR | Buy Now | MorphoSys | — | — | — | Downgrade | Overweight → Equal-Weight | Get Alert | |
| 05/24/2021 | MOR | Buy Now | MorphoSys | — | — | → $28 | Upgrade | Equal-Weight → Overweight | Get Alert | |
| 11/25/2020 | MOR | Buy Now | MorphoSys | — | — | — | Initiates | → Equal-Weight | Get Alert |
Market Resources
Trading Tools & Education
- Benzinga Pro Trading Platform
- Options Trading Strategies and News
- Stock Market Trading Ideas and Analysis
- Technical Analysis Charts and Indicators
- Fundamental Analysis and Valuation
- Day Trading Guides and Strategies
- Live Investor Events
- Pre-market Stock Analysis and News
- Cryptocurrency Market Analysis and News
Ring the Bell
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.
© 2026 Benzinga | All Rights Reserved